Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACE Combined With "Target Immune" Therapy for First-line Treatment Compared With Intravenous Chemotherapy in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: A Prospective, Multicenter, Open, Real-World Clinical Study

NCT05247996 is registered in ClinicalTrials.gov with The Central Hospital of Lishui City as lead sponsor.

NCT NCT05247996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05247996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACE Combined With "Target Immune" Therapy for First-line Treatment Compared With Intravenous Chemotherapy in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: A Prospective, Multicenter, Open, Real-World Clinical Study
Lead sponsor
The Central Hospital of Lishui City
Phase
Not applicable
Overall status
Unknown status
Start date
March 1, 2022
Completion date
December 31, 2023
Enrollment
98 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholangiocarcinoma